Meeting - Latest News:

ADVAC 2020
11 to 22 May, 2020
Veyrier du Lac (near Annecy) France

ADVAC 2020 is cancelled.

Due to the increasing travel restrictions and flight cancellations caused by COVID-19 and considering the policies of the organizing institutions, co-sponsor institutions and their government/umbrella institutions, as well as individual discussions and interactions with a number of the ADVAC Scientific Committee and lecturers, the decision has been taken jointly by the Mérieux Foundation and the University of Geneva to cancel this year’s ADVAC

The 21st ADVAC will now take place from 10 to 21 May 2021.  

In May 2019, an overview of IABS’ mission and activities was presented at the U.S. Veterinary Biologics Training Program. The training program is co-sponsored by the USDA APHIS Center for Veterinary Biologics, the USDA APHIS National Veterinary Services Laboratories and the ISU College of Veterinary Medicine’s Institute for International Cooperation in Animal Biologics (IICAB).

Read more

View the speaker slides from the 3Rs meeting, NIH, Bethesda : folder click here

View the meeting webpage Here

Report now available Here

IABS Presentation to the U.S. Veterinary Biologics Training Program

In May 2018, an overview of IABS’ mission and activities was presented at the U.S. Veterinary Biologics Training Program. The training program is co-sponsored by the USDA APHIS Center for Veterinary Biologics, the USDA APHIS National Veterinary Services Laboratories and the ISU College of Veterinary Medicine’s Institute for International Cooperation in Animal Biologics (IICAB).  The IICAB was founded in 1995 by the USDA Animal and Plant Health Inspection Service and Iowa State University. In June 1998, the IICAB received designation as a component of the World Organization for Animal Health (OIE) Collaborating Centre for the Diagnosis of Animal Diseases and Vaccine Evaluation in the Americas. The designation is shared with the USDA APHIS National Veterinary Services Laboratories (NVSL) and Center for Veterinary Biologics (CVB). 

The first Veterinary Biologics Training Program was held in June 1996 at the ISU College of Veterinary Medicine. The training program has been offered each year since then. More than 2600 individuals have attended the program including over 740 international participants from 90 different countries. More than 150 participants attended in 2018.  The program is known worldwide as a premier training program in immunology and veterinary vaccines. Many individuals who have participated in the training continue to be actively involved with veterinary biologics issues and activities world-wide.

Training Program participants were keenly interested in IABS and had many questions.  Complimentary IABS Membership for 2018-2019 was offered to participants.  IABS is looking forward to some of the new members attending upcoming conferences and workshops and becoming more actively involved with our organization.

Respectfully submitted,

Rick Hill, IABS Communication Committee Chair

IABS “3R” Conferences Highlighted in Presentation at the 10th World Congress on Alternatives and Animal Use in the Life Sciences.

August 24, 2017, an overview of IABS’ “3R” Conferences, Symposia and Workshops was included in a presentation at the vaccine session at the 10^th World Congress on Alternatives and Animal Use in the Life Sciences in Seattle Washington (See Summary Slide below).  The World Congress are periodic scientific meetings with emphasis on the latest technologies for reduction and replacement of animals and innovations in approaches to ethics, animal welfare and public policy.   Interestingly, the World Congress’ first meeting was in 1993, within one year of the IABS’s first Langen Symposium.  The 11^th World Congress is scheduled for 2020 in the Netherlands. 

In general, World Congress participants were aware of IABS’ leadership in the “3R” and Animal “Alternatives” arena and several inquired about the status of future IABS conferences.   The meeting presented an opportunity to discuss IABS overall, but also the organizations strategic priority to host “3R” related meetings by the North American and European Affiliates.

Respectfully submitted,

Rick Hill, IABS Communication Committee Chair

IABS is pleased to announce a valuable new book written by Board Member Dr. Rebecca Sheets titled Fundamentals of Biologicals Regulation:  Vaccines & Biotechnology Medicines. Dec. 2017, published by Elsevier’s imprint Academic Press.

For more information, please see https://www.elsevier.com/books/fundamentals-of-biologicals-regulation/sheets/978-0-12-809290-3

French speaking visitors can listen to the interviews of Dr. Stanley Plotkin and Dr. Marc Bonneville, during the IABS65 anniversary ceremony in Lyon

The interviews are available here : https://www.lyondemain.fr/iabs-lyon-coronavirus-vaccins-standardisation-merieux-biologie-lyonbiopole-stanley-plotkin-marc-bonneville-maladies-infections-conference/

Job Opportunity

Associate / Director CMC Statistician

The CMC Statistician is a key member of the Technical Development organization responsible for supporting the integration of statistical strategy throughout CMC. In this role you will contribute directly to advancing Moderna’s portfolio of products from development to commercial manufacturing, and help build technical platforms for a rapidly expanding pipeline. You will collaborate as a key project resource and team member with scientists and engineers working on the forefront of mRNA science. You will design experiments and develop predictive models for technical processes and analytical methods.

At Moderna we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.

We have a clear mission to propel the field of mRNA science forward and deliver new medicines to patients and a unique vision for how to achieve this mission.

LinkedIn => https://www.linkedin.com/jobs/view/2220730661/?refId=WDm3J%2FTPRoSWNZGCPHAWkA%3D%3D